CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 98 enrolled
Drug / intervention
No interventionsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02581098
NCT02581098N/ACompleted
CompareCT.gov

Novel Regulators of Wound Angiogenesis and Inflammation

Indiana University·observational·Posted Oct 20, 2015·Updated Apr 25, 2024

In Brief

An observational study evaluating No interventions for Diabetes Mellitus and 5 related conditions. Completed, enrolled 98 participants across 4 sites.

Detailed Summary

This study aims to determine if elevated wound-edge endothelial miR-200b is a barrier to wound healing in diabetic patients and also to determine if ex vivo supplementation of miR-21 mimic and recombinant MFG-E8 resolve inflammation in wound macrophages isolated from NPWT sponges from diabetic wounds. This study will enroll 124 (60 in the miR-200b arm and 64 in the miR21 arm) Diabetic Wound patients who have wound tissue oxygenation adequate to support wound healing and will be in the study for 14 weeks that includes 4 study visits.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Foot Ulcer, Ulcer, Diabetic Foot Ulcer, Wound, Wound Heal
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 20, 2015
Enrollment StartAug 1, 2015
Primary CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 10.7 years ago

Interventions

No interventionsother

No interventions